KPV: The Anti-Inflammatory Fragment Without the Pigment

Abstract — the short version

KPV is the short name for lysine-proline-valine — the last three amino acids (a tripeptide, a chain of just three amino-acid building blocks) of a longer natural hormone called alpha-melanocyte-stimulating hormone (alpha-MSH), the hormone responsible for skin pigmentation. In cell and animal studies, KPV calms an overactive inflammatory response in the gut lining without the skin-darkening (pigmentary) effect the full-length hormone carries — its job is the calming action, with the pigment job dropped.

Every finding described on this page comes from cells in a dish or from mice; no human trial of KPV has been published, so nothing here describes a human dose, a human outcome, or medical guidance of any kind.

Definition and structure

KPV's full name, KPV (Lysine-Proline-Valine), is literally the one-letter codes for its three residues: lysine (K), proline (P), and valine (V). Chemically it is L-lysyl-L-prolyl-L-valine, molecular formula C16H30N4O4, corresponding to residues 11-13 — the C-terminal sequence — of alpha-MSH. It is categorized in the literature as a melanocortin-derived anti-inflammatory tripeptide: a fragment of a melanocortin hormone that keeps one of the parent molecule's biological jobs while losing another.

Mechanism of action

KPV retains the anti-inflammatory activity of its parent hormone while lacking its pigmentary (melanogenic) action. In research models it dampens inflammation primarily by suppressing two intracellular signaling pathways, NF-kB and the MAP kinases — chemical switches inside cells that, when active, turn on inflammation — and by reducing the production of pro-inflammatory signaling molecules called cytokines. In the gut, KPV is taken up directly into lining cells through a transporter called PepT1, which becomes more active specifically in inflamed tissue, meaning the peptide is preferentially delivered to the site where it is needed. Its identified mechanism targets are: PepT1 (SLC15A1), the NF-kB transcriptional machinery, MAP kinases, and pro-inflammatory cytokine networks including IL-1beta and TNF-alpha.

Evidence review

A 2024 study combined KPV with the immunosuppressant FK506 in a PepT1-targeted nanoparticle and found it improved both acute and chronic colitis in mice beyond either agent alone, restoring tight-junction proteins and lowering inflammatory cytokines ^[1]. A 2017 study delivered KPV orally via hyaluronic-acid-functionalized nanoparticles embedded in a chitosan/alginate hydrogel and found this targeted formulation reduced colitis severity in mice more effectively than non-targeted delivery, preventing mucosal damage and accelerating healing ^[2].

Earlier mechanistic work established that KPV is transported into human intestinal epithelial cells via PepT1, and that nanomolar concentrations reduce NF-kB and MAP-kinase activation and cytokine secretion in epithelial and immune cells, with oral KPV reducing colitis severity in mice ^[3]. A related 2008 study found KPV reduced colonic inflammation across multiple mouse colitis models, including in mice lacking the MC1R receptor — indicating the anti-inflammatory action does not depend on the same receptor responsible for pigmentation ^[4]. A comprehensive 2008 review situates KPV among related tripeptides showing protective effects across fever, dermatitis, vasculitis, and gastrointestinal and arthritic models, explicitly delineating it as an anti-inflammatory alternative to full alpha-MSH because it preserves the anti-inflammatory job while dropping the pigmentary one ^[5].

Reported effects, cautions and safety profile

No community-reported anecdotal signals and no itemized safety-caution list exist for KPV in the reviewed literature — a direct reflection of its evidence stage. Every finding to date is a cell or animal result, so there is no recorded human experience, anecdotal or otherwise, to describe.

The cautions that do apply follow from the state of the evidence itself. No published human clinical trial of KPV exists, so its human dosing, efficacy, and safety profile are entirely unestablished ^[5]. KPV is a small peptide that is readily broken down by enzymes, which is why much of the current literature is delivery and formulation work — nanoparticle and hydrogel carriers engineered to keep it intact long enough to act ^[1][2]. Claims made for KPV in gut-health or skin contexts outside these controlled formulations outrun what the mechanistic and preclinical evidence actually supports, and KPV is sold only as a laboratory research chemical, not as an approved drug or dietary supplement in any major jurisdiction.

Position within the functional taxonomy

KPV's job on this desk is barrier-level inflammation control — a narrowly scoped, single-tissue anti-inflammatory action, in contrast with the lead compound's broader systemic immune-priming role covered at thymosin alpha-1. See how the five compare directly on the comparison page.